Boai NKY Medical Holdings Ltd
SZSE:300109

Watchlist Manager
Boai NKY Medical Holdings Ltd Logo
Boai NKY Medical Holdings Ltd
SZSE:300109
Watchlist
Price: 16.81 CNY -2.72% Market Closed
Market Cap: 8.1B CNY
Have any thoughts about
Boai NKY Medical Holdings Ltd?
Write Note

Boai NKY Medical Holdings Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Boai NKY Medical Holdings Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Boai NKY Medical Holdings Ltd
SZSE:300109
Operating Income
ÂĄ445m
CAGR 3-Years
54%
CAGR 5-Years
19%
CAGR 10-Years
31%
Zhejiang Juhua Co Ltd
SSE:600160
Operating Income
ÂĄ1.8B
CAGR 3-Years
81%
CAGR 5-Years
3%
CAGR 10-Years
27%
Hengli Petrochemical Co Ltd
SSE:600346
Operating Income
ÂĄ13.4B
CAGR 3-Years
-19%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Satellite Chemical Co Ltd
SZSE:002648
Operating Income
ÂĄ7.4B
CAGR 3-Years
7%
CAGR 5-Years
36%
CAGR 10-Years
31%
Jiangsu Eastern Shenghong Co Ltd
SZSE:000301
Operating Income
ÂĄ52.9m
CAGR 3-Years
-78%
CAGR 5-Years
-51%
CAGR 10-Years
-14%
Rongsheng Petrochemical Co Ltd
SZSE:002493
Operating Income
ÂĄ12.1B
CAGR 3-Years
-25%
CAGR 5-Years
38%
CAGR 10-Years
39%
No Stocks Found

Boai NKY Medical Holdings Ltd
Glance View

Market Cap
8.2B CNY
Industry
Chemicals

Boai NKY Medical Holdings Ltd., founded in the heartland of innovation in Henan Province, China, traces its roots back to an era when the world was rapidly advancing in medical technologies yet still bustling with unmet needs for specialized medical supplies. The company pioneered its focus on producing medical polymer materials and channeled its expertise into the creation of polyvinyl pyrrolidone (PVP), a versatile substance used in pharmaceuticals, cosmetics, and various medical applications. This single compound laid the foundation for the firm's ascent, offering it the placement in the global market where its robust application spans from being a pharmaceutical binder to a blood plasma substitute. The magic of Boai NKY lies in its ability to marry scientific research with commercial execution, ensuring its products meet stringent international standards, thereby opening doors to markets in over 50 countries. The company generates revenue by leveraging its strong manufacturing capabilities and R&D investments. This ensures a steady stream of innovative products catering to the global health industry. Boai NKY's business model diversifies risk by spreading its expertise across biomedicine, cosmetics, agriculture, and food sectors, creating a symbiotic revenue framework. By maintaining a diverse product portfolio and nurturing strategic partnerships, the company builds resilience against market volatility and economic downturns. Its revenue is bolstered not only by domestic sales but by a prominent international presence supported by a network of subsidiaries and distributors. This global footprint ensures a stable cash flow, while continuous investment in technology and quality assurance sustains Boai NKY at the forefront of the competitive chemical manufacturing landscape.

Intrinsic Value
12.92 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Boai NKY Medical Holdings Ltd's Operating Income?
Operating Income
445m CNY

Based on the financial report for Sep 30, 2024, Boai NKY Medical Holdings Ltd's Operating Income amounts to 445m CNY.

What is Boai NKY Medical Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
31%

Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Boai NKY Medical Holdings Ltd have been 54% over the past three years , 19% over the past five years , and 31% over the past ten years .

Back to Top